Biodesix Announced Its Observational Registry INSIGHT Study Of VeriStrat Has Completed Enrollment Of 5,000 Non-small Cell Lung Cancer Patients, To Further Validate The Utility Of The VeriStrat Test, A Prognostic Blood-Based Host Immune Classifier
Portfolio Pulse from Benzinga Newsdesk
Biodesix has completed enrollment of 5,000 non-small cell lung cancer patients in its INSIGHT study to further validate the utility of the VeriStrat test, a prognostic blood-based host immune classifier.
June 27, 2023 | 10:16 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Biodesix's completion of enrollment in the INSIGHT study for VeriStrat test may positively impact the company's stock in the short term.
The completion of enrollment in the INSIGHT study indicates progress in the validation of the VeriStrat test. This may lead to increased adoption of the test, potentially boosting Biodesix's revenues and positively impacting its stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100